Market Cap 92.57B
Revenue (ttm) 40.10B
Net Income (ttm) 3.29B
EPS (ttm) N/A
PE Ratio 10.49
Forward PE 10.10
Profit Margin 8.21%
Debt to Equity Ratio 1.21
Volume 9,860,100
Avg Vol 4,784,672
Day's Range N/A - N/A
Shares Out 2.03B
Stochastic %K 10%
Beta 0.53
Analysts Sell
Price Target $40.39

Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephr...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 8047 5000
Website: www.gsk.com
Address:
79 New Oxford Street, London, United Kingdom
Financial_Doc
Financial_Doc Oct. 24 at 2:59 PM
$GSK what's going on here after FDA approval?
1 · Reply
OpenOutcrier
OpenOutcrier Oct. 24 at 12:23 PM
$GSK (-5.0% pre) GSK shares fall as narrow approval of blood cancer drug limits US relaunch https://ooc.bz/l/81736
0 · Reply
Paulzk
Paulzk Oct. 24 at 10:21 AM
$GSK Not the final word on GSK multiple myeloma , another in phase 2 , phase 1 and 2 newly registered. Many drugs in the pipeline. buy the dip https://www.gsk.com/en-gb/innovation/pipeline/
0 · Reply
AlertsAndNews
AlertsAndNews Oct. 24 at 2:36 AM
$GSK FDA Approves Blenrep for Relapsed/Refractory Multiple Myeloma GSK announced the U.S. FDA approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma after at least two prior therapies. The approval was supported by the phase III DREAMM-7 trial, which showed a 51% reduction in risk of death and tripled median progression-free survival versus a daratumumab-based regimen.
0 · Reply
drewfin87
drewfin87 Oct. 23 at 9:55 PM
$GSK what’s up with the price action at the end of today? That bounce off of news was sold off so fast that I thought it was a glitch…
2 · Reply
SuperGreenToday
SuperGreenToday Oct. 23 at 9:49 PM
$GSK Share Price: $46.70 Contract Selected: Nov 14, 2025 $45 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.14 – $2.61 Potential Upside: 58% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Whytheykeepmutingme
Whytheykeepmutingme Oct. 23 at 9:15 PM
$GSK fda approval is bad news?
0 · Reply
OptionRunners
OptionRunners Oct. 23 at 8:01 PM
$GSK Blenrep has been approved by the US FDA for treating relapsed or refractory multiple myeloma. The DREAMM-7 trial showed a 51% reduction in risk of death and tripled median outcomes, with interim first-line efficacy and safety data expected by early 2028.
0 · Reply
CrispDry
CrispDry Oct. 23 at 8:01 PM
$GSK the heck?
0 · Reply
levans80
levans80 Oct. 23 at 7:59 PM
$GSK Closed out some call options right before the bell. Nice profit on that spike into close.
0 · Reply
Latest News on GSK
US FDA approve GSK's blood cancer treatment

Oct 23, 2025, 4:05 PM EDT - 1 day ago

US FDA approve GSK's blood cancer treatment


GSK's Hidden Growth Engines Beyond HIV And Oncology

Oct 9, 2025, 1:22 PM EDT - 15 days ago

GSK's Hidden Growth Engines Beyond HIV And Oncology


GSK turns to insider to be next CEO — and the stock rallies

Sep 29, 2025, 4:46 AM EDT - 26 days ago

GSK turns to insider to be next CEO — and the stock rallies


Who is GSK's next CEO Luke Miels?

Sep 29, 2025, 4:20 AM EDT - 26 days ago

Who is GSK's next CEO Luke Miels?


GSK names Luke Miels as CEO designate

Sep 29, 2025, 2:07 AM EDT - 26 days ago

GSK names Luke Miels as CEO designate


FDA approves drug that Trump due to suggest as autism treatment

Sep 22, 2025, 4:55 PM EDT - 4 weeks ago

FDA approves drug that Trump due to suggest as autism treatment


GSK Says It Will Spend $30B on U.S. Manufacturing and R&D

Sep 16, 2025, 7:01 PM EDT - 5 weeks ago

GSK Says It Will Spend $30B on U.S. Manufacturing and R&D


Dividend Income Summary: Lanny's July 2025 Summary

Sep 15, 2025, 7:44 AM EDT - 5 weeks ago

Dividend Income Summary: Lanny's July 2025 Summary

BNL BNS CM CSCO IRM ITW LEG


GSK's antibiotic drug gepotidacin gets priority review by FDA

Aug 11, 2025, 2:15 AM EDT - 2 months ago

GSK's antibiotic drug gepotidacin gets priority review by FDA


GSK plc (GSK) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 5:56 PM EDT - 3 months ago

GSK plc (GSK) Q2 2025 Earnings Call Transcript


GSK expects annual sales and profit at top end of forecast range

Jul 30, 2025, 2:12 AM EDT - 3 months ago

GSK expects annual sales and profit at top end of forecast range


GSK's blood cancer drug gets EU approval for multiple myeloma

Jul 24, 2025, 12:27 PM EDT - 3 months ago

GSK's blood cancer drug gets EU approval for multiple myeloma


Financial_Doc
Financial_Doc Oct. 24 at 2:59 PM
$GSK what's going on here after FDA approval?
1 · Reply
OpenOutcrier
OpenOutcrier Oct. 24 at 12:23 PM
$GSK (-5.0% pre) GSK shares fall as narrow approval of blood cancer drug limits US relaunch https://ooc.bz/l/81736
0 · Reply
Paulzk
Paulzk Oct. 24 at 10:21 AM
$GSK Not the final word on GSK multiple myeloma , another in phase 2 , phase 1 and 2 newly registered. Many drugs in the pipeline. buy the dip https://www.gsk.com/en-gb/innovation/pipeline/
0 · Reply
AlertsAndNews
AlertsAndNews Oct. 24 at 2:36 AM
$GSK FDA Approves Blenrep for Relapsed/Refractory Multiple Myeloma GSK announced the U.S. FDA approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma after at least two prior therapies. The approval was supported by the phase III DREAMM-7 trial, which showed a 51% reduction in risk of death and tripled median progression-free survival versus a daratumumab-based regimen.
0 · Reply
drewfin87
drewfin87 Oct. 23 at 9:55 PM
$GSK what’s up with the price action at the end of today? That bounce off of news was sold off so fast that I thought it was a glitch…
2 · Reply
SuperGreenToday
SuperGreenToday Oct. 23 at 9:49 PM
$GSK Share Price: $46.70 Contract Selected: Nov 14, 2025 $45 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.14 – $2.61 Potential Upside: 58% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Whytheykeepmutingme
Whytheykeepmutingme Oct. 23 at 9:15 PM
$GSK fda approval is bad news?
0 · Reply
OptionRunners
OptionRunners Oct. 23 at 8:01 PM
$GSK Blenrep has been approved by the US FDA for treating relapsed or refractory multiple myeloma. The DREAMM-7 trial showed a 51% reduction in risk of death and tripled median outcomes, with interim first-line efficacy and safety data expected by early 2028.
0 · Reply
CrispDry
CrispDry Oct. 23 at 8:01 PM
$GSK the heck?
0 · Reply
levans80
levans80 Oct. 23 at 7:59 PM
$GSK Closed out some call options right before the bell. Nice profit on that spike into close.
0 · Reply
OptionRunners
OptionRunners Oct. 23 at 7:58 PM
$GSK spiking into the close
0 · Reply
Wolly99
Wolly99 Oct. 22 at 7:50 PM
$ALT I still find it crazy interesting that $GSK is building out their clinical imaging in hepatology/renal/etc…but the verbiage suggests current liver projects. The fact that they prefer experience with “clinical radiology” and “quantitative analysis” would refer to only a could have very MASH-relevant MRI biomarkers: MRE, PDFF and cT1. Quantitative MRI isn’t really a thing outside of these in the clinical setting. Recall that GSK has the only “unpaired” FGF21 asset - meaning the other FGFs (efrux and pegoza) hav been bought and are now linked to GLP-1s (sema and survodutide) as part of a full obesity/MASLD/MASH pipeline. GSK still needs the GLP-1 part on the front end. I think they’d be wise to partner/bo pemvi, as it’s the only GLP-1 that is p3 ready in the US, and with Glucagon, it makes so much sense.
1 · Reply
look2theblue
look2theblue Oct. 22 at 6:31 PM
$ITRM Backed by $PFE science. $35M marketcap in a $10B marketspace, 14+ years of patent life. $PFE isn't going to concede the UTI market to $GSK this will get resolved.
0 · Reply
look2theblue
look2theblue Oct. 22 at 2:59 PM
$ITRM the single biggest check in Iterum’s favor for an acquisition by $PFE is that $PFE is unlikely to just roll over and concede the entire multibillion dollar UTI market to $GSK and Blujepa for the next 15 years.
1 · Reply
BTC321
BTC321 Oct. 22 at 11:55 AM
$NVAX 🚨 $NVAX just dumped a site for $60 M cash and chopped $230 M in future costs. CEO calls it “leaner and more agile.” That’s not cost cutting — that’s house-cleaning before company shows up with a checkbook. 💼 Shah Capital’s been whispering “strategic options” for months. Add the new peer-reviewed mucosal immunity data (IgA antibodies — the real deal) and you’ve got a biotech that suddenly looks 🔥 to Big Pharma. $CSL? $GSK? Sanofi?$SNY $MRK or Serum Institute? Someone’s running the numbers. 🧮 The street’s asleep. Shorts are drunk. Watch what happens when the phone rings. ☎️ #NVAX #Novavax #M&A #TakeoverWatch #Biotech #ShortSqueeze #ScienceWins next $BYND
0 · Reply
sergiustrading
sergiustrading Oct. 22 at 9:33 AM
0 · Reply
Quantumup
Quantumup Oct. 21 at 8:31 PM
Clear Street🏁 $SGMT Buy/$29 $MDGL Boston Pharma - $GSK $IVA VKTX $ALGS Clear Street said: We initiate coverage of SGMT with a Buy, reflecting the highly attractive profile of once-daily oral denifanstat—an asset leveraging robust multi-modal biology akin to FGF21 analogs, which have recently driven prominent M&A activity within the MASH space. Denifanstat's exceptional P2b F2-F3 data, outstanding P3 acne results, and forward-looking development plans for F4C in combination with Madrigal Pharmaceuticals' (MDGL: Nasdaq, Buy, $431 PT) REZDIFFRA, all underpinned by a solid $135.5M cash position (runway into 2027), and anticipated readouts from ongoing P1 trials, together position SGMT as a compelling growth story. Even under conservative valuation metrics, comparable to Boston Pharma's recent $1.2B upfront acquisition, our $29 PT implies substantial upside relative to SGMT's current $188M EV.
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 21 at 1:31 PM
$ALT I asked ChatGPT for the most likely acquirers. Interestingly they had $NVO as #1, followed by Roche, $GILD , $PFE , and $GSK . Any of those make sense to me - we’ll see what happens after the 48 week data is released soon 🕰️
0 · Reply
aletz
aletz Oct. 21 at 1:18 PM
$ALGS all the antigens have not rebounded significantly and stayed almost the same level it left after stopping taking pevy, absolutely ground breaking compared to the current standard of care. Big pharmas will be watching very closely, but ALGS has no interest of letting pevy go now. $GSK $RHHBY $GILD
1 · Reply
GTDaytona
GTDaytona Oct. 21 at 12:03 PM
0 · Reply
GTDaytona
GTDaytona Oct. 21 at 12:02 PM
0 · Reply
sweet_Journey
sweet_Journey Oct. 21 at 9:55 AM
$SPRO $GSK 🔥
0 · Reply